Back

Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy in complex settings Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ioannis Thymis

Attikon University Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Effects of SGLT2i in the perioperative care of cardiac surgery: a systematic review and meta-analysis of randomised controlled trials
Mr K. Chagas (Itaperuna, BR)
Abstract
Presentation thumbnail
Cardiovascular outcomes by baseline blood pressure control status in persons with type 2 diabetes at high cardiovascular risk treated with oral semaglutide
Professor N. Poulter (London, GB)
Abstract
Presentation thumbnail
Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration
Doctor J. Lamprea Montealegre (San Francisco, US)
Abstract
Presentation thumbnail
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and extra-valvular cardiac damage undergoing TAVI
Doctor G. Vincelli (Rome, IT)
Abstract
Presentation thumbnail
Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety
Mr J. Maldonado Flores (Tijuana, MX)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy in complex settings

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of glucagon like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on vascular function and myocardial work index in patient with type-2 diabetes
28 August 2020
thumbnail
Congress Presentation
Real world risk of major outcomes for type 2 diabetes with stable coronary artery disease without prior MI or stroke and THEMIS-like patients using the SNDS French nationwide claims database
30 August 2020
thumbnail
Congress Presentation
Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis
31 August 2024
thumbnail
Congress Presentation
A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources